General Line
+603 7841 4000
Dr. Poh is a senior lecturer with the University of Malaya and Consultant Respiratory Physician at both UMMC and UMSC. Formerly a graduate of University of Malaya, he has worked both locally under the mentorship of distinguished professor Liam Chong Kin and abroad in Newcastle, UK being trained in areas of lung cancer amongst many other respiratory illnesses. He is skillful in pleural ultrasound, bronchoscopy and pleuroscopy.
Prior to his return to Malaysia, he successfully passed the Specialty Certificate Examination in Respiratory Medicine, awarded by the Royal College of Physicians UK and British Thoracic Society.
Dr Poh is a top ranked academic in the country and was awarded the prestigious best lecturer award by the University of Malaya in 2018. He is well respected and liked by peers and his students, both locally and internationally.
Dr Poh treats a variety of respiratory conditions and is recognized as an expert in lung cancer. He heads the special interest group for lung cancer at the Malaysian Thoracic Society. He is also affiliated to the International Association for the Study of Lung Cancer, European Society of Medical Oncology, Asian Pacific Society of Respirology, Malaysian Thoracic Society, American College of Chest Physicians and Royal College of Physicians (UK). He is actively involved in global clinical research work.
As a doctor, he is known to be kind, sincere and empathic and is very popular amongst his patients.
Get to know me better : https://umexpert.um.edu.my/ernestpoh.html
2018
Poh ME, Liam CK, Rajadurai P, Chai CS. Epithelial-to-Mesenchymal Transition (EMT) Causing Acquired Resistance to Afatinib in a Patient with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma (Manuscript ID: JTD-18-141) (Accepted for publication by Journal of Thoracic Disease on 19 June 2018) (ISI-Indexed)
2017
Chai CS, Liam CK, Poh ME et al.(2017). Epidermal growth factor receptor mutation in newly diagnosed lung adenocarcinoma. J Respir Med Lung Dis; 2(2): 1016. (ISI-Indexed)
2016
Chai CS, Liam CK, Poh ME, et al. (2016). Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients. European Respiratory Journal. 48 (suppl 60) :PA4840. (ISI-Indexed)
2016
Chai CS, Liam CK, Poh ME, et al.(2016). Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma. European Respiratory Journal; 48 (suppl 60) : OA3341 (ISI-Indexed)
2015
Chai CS, Liam CK, Poh ME, et al. (2015). Treatment outcome of Malaysian patients with advanced lung adenocarcinoma. Annals of Oncology. 26 (Supplement 9): ix 125 – ix 1457 (ISI-Indexed)
2014
Poh, M. E., Liam, C. K., Ng, K. P., Tan, R. X. 2014. Mycobacterium Brisbanense Species Nova Isolated From a Patient With Chronic Cavitary Lung Infection Chest. (Tier 1, Impact Factor = 7.132) (ISI-Indexed)
2014
20.Liam CK, Pang YK and Poh ME. EGFR Mutations in Asian Patients with Advanced Lung Adenocarcinoma. Journal of Thoracic Oncology. 2014; 9(9):e70-1 (ISI-Indexed)
2014
21.Poh ME, Liam CK, Tan JL, et al. Acrometastasis from an epidermal- growth-factor-receptor (EGFR) mutation-positive lung adenocarcinoma. Cancer Treatment Communications. 2014; Volume 2 (Issues 2-3):21-23 (SCOPUS-Indexed)
2013
Liam CK, Poh ME, Pang YK et al. Advanced right lung adenocarcinoma with ipsilateral breast metastasis. Respirology Case Report. 2013; 1(1):20- 22 (ISI-Indexed)
2013
Poh ME, Liam CK, Pang YK, et al. Endobronchial metastases from resected renal cell carcinoma causing total lung collapse. Respirology Case Report. 2013; 1(2):26-7 (ISI-Indexed)
2007
Sim BLH, Nissapatorn V, Poh ME, et al. Toxoplasmosis: a silent opportunistic diseases in HIV/AIDS patients. Research Journal of Parasitology. 2007; 2(1):23-31 (ISI-Indexed)
